Cencora, Inc. (NYSE:COR) Shares Sold by Quantbot Technologies LP

Quantbot Technologies LP lessened its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 35.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 84,940 shares of the company's stock after selling 46,617 shares during the quarter. Cencora comprises about 0.7% of Quantbot Technologies LP's holdings, making the stock its 5th biggest holding. Quantbot Technologies LP's holdings in Cencora were worth $19,084,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Sciencast Management LP acquired a new stake in shares of Cencora during the fourth quarter worth about $243,000. Millstone Evans Group LLC purchased a new stake in shares of Cencora during the fourth quarter worth approximately $131,000. Adams Diversified Equity Fund Inc. increased its stake in shares of Cencora by 17.1% during the fourth quarter. Adams Diversified Equity Fund Inc. now owns 81,000 shares of the company's stock worth $18,199,000 after buying an additional 11,800 shares during the period. Whittier Trust Co. increased its stake in shares of Cencora by 0.6% during the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after buying an additional 44 shares during the period. Finally, Symmetry Partners LLC increased its stake in shares of Cencora by 8.2% during the fourth quarter. Symmetry Partners LLC now owns 968 shares of the company's stock worth $218,000 after buying an additional 73 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Up 1.2 %

Cencora stock traded up $3.06 during mid-day trading on Tuesday, hitting $264.02. The company had a trading volume of 1,745,536 shares, compared to its average volume of 1,353,205. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a market cap of $51.20 billion, a price-to-earnings ratio of 37.56, a PEG ratio of 1.31 and a beta of 0.51. The business has a fifty day moving average of $248.23 and a 200 day moving average of $239.31. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $265.36.

Remove Ads

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.83%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 4,970 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the sale, the chief executive officer now directly owns 51,070 shares of the company's stock, valued at $13,022,850. This trade represents a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,648 shares of company stock worth $3,382,462. Insiders own 10.80% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on COR. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Wells Fargo & Company upped their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday. Evercore ISI upped their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Finally, Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Cencora has a consensus rating of "Moderate Buy" and an average target price of $280.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.